



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

| APPLICATION NO. | FILING DATE | FIRST NAMED INVENTOR | ATTORNEY DOCKET NO. | CONFIRMATION NO. |
|-----------------|-------------|----------------------|---------------------|------------------|
| 10/783,916      | 02/20/2004  | Chengde Wu           | 017092-0044-999     | 7123             |

20583 7590 07/31/2007  
JONES DAY  
222 EAST 41ST ST  
NEW YORK, NY 10017

|          |
|----------|
| EXAMINER |
|----------|

DAVIS, ZINNA NORTHINGTON

|          |              |
|----------|--------------|
| ART UNIT | PAPER NUMBER |
|----------|--------------|

1625

|           |               |
|-----------|---------------|
| MAIL DATE | DELIVERY MODE |
|-----------|---------------|

07/31/2007

PAPER

**Please find below and/or attached an Office communication concerning this application or proceeding.**

The time period for reply, if any, is set in the attached communication.

|   |                         |                     |  |
|---|-------------------------|---------------------|--|
| <b>Response to Rule 312 Communication</b> | <b>Application No.</b>  | <b>Applicant(s)</b> |  |
|   | 10/783,916              | WU ET AL.           |  |
|   | <b>Examiner</b>         | <b>Art Unit</b>     |  |
|   | Zinna Northington Davis | 1625                |  |

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

1. ☒ The amendment filed on 14 June 2007 under 37 CFR 1.312 has been considered, and has been:

a) ☐ entered.

b) ☒ entered as directed to matters of form not affecting the scope of the invention.

c) ☐ disapproved because the amendment was filed after the payment of the issue fee.

Any amendment filed after the date the issue fee is paid must be accompanied by a petition under 37 CFR 1.313(c)(1) and the required fee to withdraw the application from issue.

d) ☐ disapproved. See explanation below.

e) ☐ entered in part. See explanation below.

*The Petition for Correction of Inventorship under 37 C.F.R. 1.48 (a) has been approved. The inventorship has been corrected to delete the inventors, George W. Holland, Jamal Kassir, and Junmei Wang.*



Zinna Northington Davis  
Primary Examiner  
Art Unit: 1625



Express Mail No.: EB 132601945 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

|                 |   |                      |  |
|-----------------|---|----------------------|--|
| Application of: | Wu, et al.  | Confirmation No.:    | 7123                                   |
| Serial No.:     | 10/783,916  | Art Unit:            | 1625                                   |
| Filed:          | February 20, 2004   | Examiner:            | Davis, Z. N.                           |
| For:            | Pyridine, Pyrimidine,<br>Quinoline, Quinazoline and<br>Naphthalene Urotensin-II<br>Receptor Antagonists | Attorney Docket No.: | 017092-0044-999<br>(CAM 011104-999013) |

PETITION FOR CORRECTION OF INVENTORSHIP  
UNDER 37 C.F.R. § 1.48 (a)

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Correction of inventorship is respectfully requested under 37 C.F.R. § 1.48 (a) for the above-identified application in order to conform inventorship to the pending claims. The correct inventors of the claimed subject matter are Eric Anderson, Huong Bui, Brian Dupre, Daxin Gao, Wen Li and Chengde Wu. Thus, it is respectfully requested that George W. Holland, Jamal Kassir and Junmei Wang be deleted from named co-inventors in the above-identified application.

The requested correction is to correct an error in naming inventors that occurred without deceptive intention on the part of the above-identified persons. Statements from George W. Holland, Jamal Kassir and Junmei Wang, the persons being deleted from the named co-inventors, that the error in inventorship occurred without deceptive intention on their part, are enclosed. Also enclosed are Declarations of Eric Anderson, Huong Bui, Brian Dupre, Daxin Gao, Wen Li and Chengde Wu under 37 C.F.R. § 1.63 and a consent by Assignee, Encysive Pharmaceuticals, Inc.

06/18/2007 SDIRETA2 00000001 503013 10783916

04 FC:1464


130.00 DA

Application No. No.: 10/924,180  
Filed: August 23, 2004  
Page 2 of 2

A fee of \$130.00 is believed due for this submission. Should any additional fees be due for this submission or to avoid abandonment of the application, please charge such fees to Jones Day Deposit Account No. 50-3013.

Date: June 14, 2007

Respectfully submitted,



Dale L. Rieger (Reg. No. 43,045)

**JONES DAY**

222 East 41st Street

New York, New York 10017

(858) 314.1188

*Enclosures*